Fulvestrant: all 236 studies that test it

Page 3 of 3. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.

• A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast CancerCompletedNCT02333370Phase 1
• Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid TumoursCompletedNCT02260661Phase 1
• Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by SurgeryCompletedNCT02219789Phase 1
• Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABCWithdrawnNCT02140437Phase 2
• A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast CancerCompletedNCT02137083Phase 2
• The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast CancerStatus unknownNCT02072512Phase 2
• Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast CancerStatus unknownNCT02000193Phase 2
• Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing SurgeryActive, not recruitingNCT01953588Phase 3
• Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFRCompletedNCT01556191Phase 2
• MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast CancerCompletedNCT01344031Phase 1
• BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast CancerCompletedNCT01339442Phase 1
• Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal WomenStatus unknownNCT01266213Phase 2
• Study of AFP464 +/- Faslodex in ER + Breast CancerTerminatedNCT01233947Phase 2
• A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA GeneCompletedNCT01219699Phase 1
• Trial of ZD6474 and Faslodex in Non-Small Cell Lung CancerWithdrawnNCT01004419Phase 1
• Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)CompletedNCT00944918Phase 3
• A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)Status unknownNCT00927511Phase 2
• Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast CancerCompletedNCT00811369Phase 2
• Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast CancerSuspendedNCT00738777Phase 2
• Second Line Breast Cancer TrialCompletedNCT00635713Phase 3
• Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast CancerCompletedNCT00629616Phase 2
• Efficacy and Safety of 500mg of FulvestrantActive, not recruitingNCT00585507Phase 2
• Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular StudiesCompletedNCT00417430Phase 2
• Faslodex 500mg Multiple Dose Tolerability Study in BC PatientsCompletedNCT00328120Phase 1
• Faslodex Advanced Breast Cancer Local Chinese StudyCompletedNCT00327769Phase 3
• SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast CancerCompletedNCT00272740Phase 2
• Fulvestrant in Treating Patients With Advanced Prostate CancerCompletedNCT00244998Phase 2
• A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast CancerCompletedNCT00241449Phase 3
• A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast CancerCompletedNCT00234403Phase 2
• Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast CancerCompletedNCT00146601Phase 2
• Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the BreastStatus unknownNCT00126464Not applicable
• Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00100854Phase 2
• Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast CancerCompletedNCT00093002Phase 2
• The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast CancerCompletedNCT00065325Phase 3
• ICI 182780 in Treating Women With Metastatic Breast CancerCompletedNCT00012025Phase 2
• ICI 182780 in Treating Women With Stage I or Stage II Primary Breast CancerTerminatedNCT00010153Phase 3

← Fulvestrant overview